The Competition and Consumer Protection Commission has initiated an in-depth Phase 2 investigation into Uniphar’s planned takeover of TouchStore, a specialist pharmacy software company, citing potential concerns about market power in the Irish pharmaceutical technology sector.
The announcement on 3 September 2026 signals heightened regulatory concern about the proposed transaction between the Dublin-headquartered pharmaceutical services group and the pharmacy management software provider. The escalation to a full investigation follows an initial Phase 1 review that raised sufficient questions to warrant deeper examination.
Key facts
- Competition and Consumer Protection Commission launched Phase 2 investigation on 3 September 2026
- Deal involves Uniphar’s acquisition of pharmacy software company TouchStore
- Investigation focuses on potential competition concerns in pharmaceutical technology market
- Phase 2 inquiry represents escalation from preliminary Phase 1 assessment
- Uniphar is a major Irish pharmaceutical distribution and services provider
Regulatory Scrutiny Intensifies
The Competition and Consumer Protection Commission has determined that the proposed merger warrants comprehensive examination under Phase 2 procedures, which involve detailed market analysis and extended timelines. This level of scrutiny is reserved for transactions that present potentially substantial competition concerns requiring thorough investigation.
Phase 2 investigations typically examine whether a proposed acquisition would significantly lessen competition in Irish markets, potentially leading to higher prices, reduced choice, or diminished innovation for consumers and businesses. The watchdog will assess the combined entity’s market position, barriers to entry for competitors, and the likelihood of maintaining effective competition in pharmacy software and related services.
The investigation will likely examine Uniphar’s existing market position across pharmaceutical distribution, retail pharmacy operations, and healthcare services, evaluating how the addition of TouchStore’s software capabilities might affect competitive dynamics. Particular attention may focus on whether the merged entity could leverage control over critical software infrastructure to disadvantage competing pharmacy operators or software providers.
Pharmaceutical Technology Market Implications
Uniphar has built a substantial presence across multiple pharmaceutical sectors, including wholesale distribution, retail pharmacy franchises, and healthcare technology solutions. The company operates across Ireland, the United Kingdom, and other European markets, positioning itself as an integrated pharmaceutical services provider.
TouchStore specialises in pharmacy management software systems that handle dispensing, inventory management, patient records, and regulatory compliance functions critical to modern pharmacy operations. Such software platforms have become essential infrastructure for retail and hospital pharmacies, creating potential concerns when control becomes concentrated in fewer hands.
The outcome of the Phase 2 investigation could significantly impact the transaction’s structure or viability. The Commission may ultimately approve the deal unconditionally, approve it subject to binding commitments from the parties, or prohibit the merger entirely if competition concerns cannot be adequately addressed. Phase 2 investigations typically conclude within several months, though complex cases may require extended timeframes.
Both companies will have opportunities to address the Commission’s concerns through submissions, data provision, and potentially proposed remedies designed to preserve competitive market conditions. The investigation reflects broader regulatory attention to digital infrastructure and platform consolidation across healthcare and technology sectors throughout Ireland and the European Union.
Reporting based on original coverage by the original source.
